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Abstract 
The cytoplasmic domain linking transmembrane segments 2 and 3 (LOOPl) of the yeast H+-ATPase was probed by the introduction 
of unique factor Xa recognition sites. Three sites, I “‘EGR 12s4EGR and I”‘EGR, representing different structural regions of the LOOP1 , 
domain, were engineered by site-specific mutagenesis of the PMAl gene. In each case, multiple amino acid substitutions were required to 
form the factor Xa sites, which enabled an analysis of clustered mutations. Both I”’ EGR and 1”‘EGR-containing mutants grew at 
normal rates, but showed prominent growth resistance to hygromycin B and sensitivity to low external pH. The engineered 12’4EGR site 
within the predicted P-strand region produced a recessive lethal phenotype, indicating that mutations G  ‘541 and F257R were not tolerated. 
Mutant I”‘EGR- and 1275EGR-containing enzymes showed relatively normal K, and V,,,,, values, but they displayed a strong 
insensitivity to inhibition by vanadate. An I”’ EGR/12”EGR double mutant was more significantly perturbed showing a reduced V,,, 
and pronounced vanadate insensitivity. The I”’ EGR site within the putative a-helical stalk region was cleaved to a maximum of 10% by 
factor Xa under non-denaturing conditions resulting in a characteristic 81 kDa fragment, whereas the I ‘75EGR site, near the end of the 
P-strand region, showed about 30-35% cleavage with the appearance of a 70 kDa fragment. A I ‘70EGR/1275EGR double mutant enzyme 
showed about 55-60% cleavage. The cleavage profile for the mutant enzymes was enhanced under denaturing conditions, but was 
unaffected by MgATP or MgATP plus vanadate. Cleavage at the I 275EGR position had no adverse effects on ATP hydrolysis or proton 
transport by the H+-ATPase making it unlikely that this localized region of LOOP1 influences coupling. Overall, these results suggest 
that the local region encompassing I 275EGR is accessible to factor Xa, while the region around I”’ EGR appears buried. Although there is 
no evidence for gross molecular motion at either site, the effects of multiple amino acid substitutions in these regions suggest that the 
LOOP1 domain is conformationally active, and that perturbations in this domain affect the distribution of conformational intermediates 
during steady-state catalysis. 
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1. Introduction 
The plasma membrane Hi-ATPase from Saccha- 
romyces cerecisiae is an electrogenic proton pump that 
couples energy from ATP hydrolysis to the active extru- 
sion of protons. It is an essential enzyme that plays a 
critical role in the maintenance of electrochemical proton 
gradients and the regulation of intracellular pH [ 1,2]. The 
H+-ATPase belongs to the P-type ATPase family of ion- 
translocating ATPases, which are found in all plant, ani- 
mal, fungal and bacterial cells, and actively transport ions 
such as H+, K+, Na+, Ca*+ and Mg’+. P-type enzymes 
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form a characteristic aspartyl-phosphate intermediate and 
exist in two principal conformational states during cataly- 
sis [3,4]. Significant sequence similarity exists between the 
various P-type ATPase members, although the greatest 
degree of sequence homology lies within the ATP hydro- 
lytic domain [5,6]. The topology of these enzymes is 
similar with the N- and C-termini residing in the cytosol 
[7-91, and the number of predicted transmembrane seg- 
ments varying between 8 and 10 [lo-151. There is general 
agreement on the topology of the first four transmembrane 
segments, while less certainty exists with the C-terminal 
elements [ 161. 
The mechanistic nature of energy coupling by P-type 
enzymes is not understood. The transmittal of energy from 
the binding and subsequent hydrolysis of ATP hydrolysis 
in a cytosolic catalytic domain to ion transport in a spa- 
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tially distinct membrane domain is expected to involve 
long-range conformational interactions [4,17,181, and di- 
verse studies involving higher eukaryotic enzymes support 
this notion [ 19-261. Genetic evidence obtained for the 
yeast H+-ATPase [27-291 also supports the concept of 
long-range conformational interactions. Furthermore, these 
studies helped define a region of the H+-ATPase, encom- 
passing transmembrane segments 1 (M 1) and 2 (M2), that 
appears to be important to the coupling process. Trans- 
membrane segments 1 and 2 are predicted to form a 
tightly-packed helical hairpin loop structure that is highly 
conformationally active [30]. Molecular dynamic simula- 
tions suggest that local perturbations in this region can be 
propagated over long distances which may be important 
for coupling to the catalytic ATP hydrolysis domain [30]. 
In addition, the inhibition of higher eucaryotic enzymes by 
therapeutic agents, which appear to interact with this re- 
gion [20,26,3 1,321, supports the prediction that perturba- 
tions of local structure within Ml and M2 are communi- 
cated to the ATP hydrolysis domain. 
How perturbations in Ml and M2 are conformationally 
linked to the catalytic ATP hydrolysis domain is not 
known. However, a likely structural candidate is the polar 
cytoplasmic loop domain (LOOP]) linking M2 and M3. 
This region is predicted to form both part of the stalk 
region and part of the catalytic ATP hydrolysis domain 
[ 16,331, along with the large central cytoplasmic loop 
domain, which links M4 and M5, and contains sites for 
ATP binding and phosphoryl transfer (D378). LOOP1 
domains from all P-type enzymes contain several highly 
conserved regions [6] and share common structural motifs 
[34]. They are predicted to form a-helical stretches at the 
N- and C-terminal portions which contribute to the ‘stalk’ 
structure, and they also are suggested to form a P-strand 
domain that functions during catalysis [ 16,331. The LOOP1 
region was originally postulated to act as a transduction 
domain based largely on the observation that Ca’+ trans- 
port appeared uncoupled from ATP hydrolysis in the 
Ca’+-ATPase following tryptic hydrolysis of RI98 in the 
P-strand region of LOOP1 [35]. While more recent tryptic 
proteolysis [36,37] and genetic studies [38,39] of residues 
in this region suggest that the perturbed enzymes are fully 
coupled, this region does appear to undergo distinct con- 
formational changes during catalysis, and these changes 
have been linked to cation movement in the Na’,K+- 
ATPase and Ca’ +-ATPase [40,4 I]. 
To further investigate structural properties of LOOP1 
that are important for the function of this region, we 
introduced unique factor Xa recognition sites, which con- 
sist of four amino acids (IE(D)GR), into the LOOP1 
domain of the yeast H+-ATPase. These sites, located in 
putative a-helical and P-strand regions, allowed us to 
explore the solvent accessibility of structural domains of 
LOOPI, and to further examine the role of LOOP1 in 
catalytic function and/or coupling by assessing the affects 
of genetic and enzymatic perturbations on the H+-ATPase. 
2. Materials and methods 
2.1. Yeast strains and cultures 
All yeast strains utilized in this study are isogenic 
derivatives of Y55 (HO gal3 MALI SUCI) [42]. Wild type 
control strain GW201 (HO ade6I trp-5-l arg4-I leu2-1 
lysl-I uru3-1 pmul::uru3/ PMAI) was obtained by select- 
ing a wild type spore from strain SH122 (HO ade6-l 
trp.5-I leu2-1 lysl-1 uru3-I pmulA::LEU2/PMAI) [27] 
that had been transformed with a 6.1 kb fragment of wild 
type DNA containing a URA3-marked PMAI gene 1271. 
All yeast cultures were grown in YEPD medium (1% yeast 
extract, 2% peptone and 2% dextrose, pH 5.7) at 22°C to 
mid-log phase ( A590 N 5). Cell growth measurements were 
made in YEPD medium with constant shaking at 21°C in 
200 ~1 aliquots of growth medium in 96 well microplates 
and monitored at A,,, with a Spectra ELBA reader 
(Tecan SLT LabInstruments). 
2.2. Site-directed mutagenesis 
Site-directed pmul mutants were constructed essen- 
tially as described by Na et al. [28]. All PMAI mutations 
prepared in phagemid vector pGW20 1, which consists of a 
6.1 kb Hind111 fragment containing a URA.?-marked PMAI 
gene [27] subcloned into phagemid vector pGEM-3zf (Pro- 
mega). Directed mutagenesis was performed as previously 
described [29] using primers 5’-CCACTGTTAAGAGA- 
ATTGAAGGTAGAATGGTTGTTACCGC for site 
FEGR, 5’-GGTAGAGCTGCTGCTATTGAAGGCA- 
GAGCCGCTGGTGGTC for site IZ7’E& &rdmAA- 
GCTGGTTCTATTGTCATTGAAGGTAGAAAGACTTT- 
GGCTAAC ACTGC fo=ite IlnEGR in the extension 
reaction. Isogenic pmal mutants were obtained by 
transplacing a 6.1 kb Hind111 pmul-mutant and URA3- 
containing fragment into yeast strain SH122 (HO ude6I 
trp5-I leu2-I lysl-I uru3-I pmulA::LEU2/PMAI) [27]. 
All pmal mutations transplaced into yeast were verified in 
viable Ura + spores, as described by [29]. 
2.3. Plasma membrane isolation and ATP hydrolysis assay 
Plasma membranes were purified from wild type and 
pmul mutant strains by centrifugation on a sucrose step- 
gradient, as previously described [43]. ATP hydrolysis 
measurements were performed in microplate assay in a 
100 ~1 volume containing 10 mM Mes/Tris pH 6.5, 25 
mM NH,Cl, 5 mM ATP, 5 mM MgCl, and 0.5-2 ,ug of 
membrane protein described, as by Monk et al. [44]. 
2.4. Factor Xa cleacage 
A typical reaction consisted of 10 ~1 of 20 mM Tris- 
HCI, pH 8.0, 100 mM NaCl, 2 mM CaC12, 25% glycerol, 
6-10 pug purified membrane protein and 2 pg factor Xa 
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(New England BioLabs). The reaction medium was incu- 
bated at 12°C for 18 h. The level of cleavage was assessed 
by SDS gel electrophoresis. 
2.5. Reconstitution and proton transport assays 
Plasma membrane vesicles were first extracted with 
deoxycholate, as previously described by Seto-Young et al. 
[43]. The extracted membranes (250 pg) were combined 
with 10 mg sonicated asolectin in a 800 ~1 volume 
containing 10 mM Hepes-Tris, pH 7.0, 100 mM KCl, 0.2 
mM EDTA, 1 mM DTT , 45% (v/v> glycerol and 0.5% 
(w/v) deoxycholate (added dropwise). The mixture was 
allowed to sit at 4°C for 5 min, and then rapidly diluted 
into 25 ml of 10 mM Hepes-Tris, pH 7.0, 100 mM KC1 
and 1 mM DTT. The mixture was centrifuged at 45 000 
rpm in a 50.2Ti rotor for 1 h. The pellet was resuspended 
in 400 ~1 of the dilution buffer and used fresh. Reconsti- 
tuted vesicles treated with factor Xa were first washed by 
resuspension in 25 ml dilution buffer and then centrifuge. 
as above. The final pellet was resuspended in 150 ~1 of 
dilution buffer. Proton transport measurements were made 
according to the method of Perlin et al. [45]. A fluores- 
cence quenching reaction volume consisted of 1 ml of 10 
mM Hepes-Tris, pH 7.0, 50 mM KCl, 5 mM ATP and 1.5 
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Fig. 1. Effect of factor Xa on wild type and IEGR-containing mutant 
H+-ATPases. Sucrose gradient purified plasma membranes (10 pgl from 
wild type (A) and pmal mutant strains carrying mutations encoding 
I”‘EGR (Bl, I’7sEGR (Cl and I’70EGR/I’75EGR (Dl were incubated 
with factor Xa (2 pgl for 18 h at 12°C in a 10 ~1 volume consisting of 
20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 2 mM CaCl, and 25% 
glycerol. The treated samples were run on 10% SDS polyacrylamide gels 
and stained with Coomassie blue. The intact H+-ATPase (M, - 100000) 
and factor Xa-induced fragments are indicated. 
PM acridine orange. The reaction was initiated by the 
addition of 5 mM MgSO,. Fluorescence intensity was 
monitored on a Perkin-Elmer LS-5 spectrofluorometer. 
2.6. SDS gel electrophoresis, Western blotting and anti- 
body pur$ication 
SDS gel electrophoresis of plasma membranes in 10% 
(w/v> pre-cast minigels (Bio-Rad) and semi-dry elec- 
troblotting of proteins was performed, as previously de- 
scribed [44]. Antibodies to the LOOP1 region were derived 
from a serum containing polyclonal whole anti-ATPase 
antibodies [29] by immuno-affinity purification utilizing a 
MalE fusion protein containing the LOOP1 region [44]. 
The antibodies were eluted with 100 mM glycine, pH 2.5, 
and then neutralized to pH 7.0 with Tris base. 
2.7. Other procedures 
Protein was determined by a modified Lowry method 
[45]. Yeast transformants were prepared by the lithium 
acetate treatment method using single-stranded carrier DNA 
[46], as described in Alkali-Cation Yeast Transformation 
Kit (BIO 101 Inc.). DNA sequencing of plasmid DNA was 
performed with the Sequenase system (United States Bio- 
chemicals). 
3. Results 
3.1. Introduction of factor Xa sites 
The cytoplasmic domain of the yeast H+-ATPase con- 
tains numerous potential cleavage sites for typical prote- 
olytic agents, such as trypsin, chymotrypsin or other com- 
monly used proteases, making it is difficult to obtain 
selective cleavage of the enzyme. Blood protease factor Xa 
requires a four amino acid recognition sequence consisting 
of ICE or D)GR for peptide bond cleavage, which limits the 
number of cleavage sites in most proteins. The yeast 
H+-ATPase has no amino acid sequence corresponding to 
a factor Xa recognition site, and it is not expected that the 
enzyme would be cleaved by this reagent. Fig. IA con- 
firms that incubation of wild type enzyme in purified 
plasma membranes under conditions optimal for factor Xa 
cleavage had no apparent affect on the H+-ATPase. Al- 
though, other membrane proteins were sensitive to incuba- 
tion with factor Xa. Identical results were obtained for 
enzyme extracted with 0.1 or 0.5% deoxycholate prior to 
incubation with factor Xa (not shown). Unique factor Xa 
sites were introduced into the LOOP1 region by site-di- 
rected mutagenesis by converting D’70ELK’73 to I”‘EGR, 
L’75VNK278 to I’75EGR and G’““EGFZ5’ to I”‘EGR. 
The first two sites fall within the putative extended cr-heli- 
cal region comprising part of the ‘stalk’ and the last site 
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Fig. 2. Schematic diagram showing LOOP1 and associated tram-membrane domains. The LOOP1 domain of the H+-ATPase is shown with predicted 
helical elements extending from transmembrane segments 2 and 3 leading into a predicted P-strand region. The relative positions of factor Xa sites 
introduced are designated by the arrows, as shown. 
falls within the P-strand region, as predicted from sec- 
ondary structure analysis [47] (Fig. 2). 
The introduction of the three factor Xa sites required 
amino acid substitutions in regions, which are believed to 
be important for progression of phosphorylated catalytic 
intermediates [48]. Mutant sequence 1254EGR was found to 
produce a recessive lethal phenotype in our conditional 
expression system indicating that these changes produced a 
severely defective enzyme. In contrast, both I”‘EGR and 
1275EGR resulted in viable enzymes displaying normal 
growth rates. Only the double site mutant containing both 
I”‘EGR and 12”EGR resulted in a viable cell with a 
reduced growth rate approximating 60% of wild type. 
Typical of pmal mutants, more subtle effects of mutations 
were observed by examining growth responses to hy- 
gromycin B and low pH growth medium, which are linked 
to electrogenic proton transport and the regulation of cyto- 
plasmic pH by the Hf-ATPase, respectively [49]. Fig. 3 
shows that the growth of all pmal mutants was less 
sensitive to hygromycin B than wild type, with the 
1275EGR-containing mutant showing the most resistance. 
A similar profile was observed for pH dependent growth, 
where all three pm&-mutants showed a diminished ability 
to grow at medium pH < 4.5 (Fig. 4). These data are 
consistent with fully functional, but kinetically inefficient 
mutant Hi-ATPases, as has been previously observed 
[45,491. 
Plasma membranes were isolated from the three viable 
pmal mutant strains. SDS-PAGE and Western blot analy- 
sis was used to confirm that the mutations required to 
construct factor Xa sites in pm~l-1”~EGR and pmal- 
1275EGR had no affect on the level of intact (M, N 100000) 
H+-ATPase in the membrane, while the double mutant, 
1170EGR/1275EGR, was reduced by about 40%. Table 1 
shows the steady-state kinetic properties of the mutant 
enzymes relative to wild type. All mutant and wild type 
enzymes showed comparable K, values. However, V,,, 
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Fig. 3. Growth sensitivity of IEGR-containing pmal mutant to hy- 
gromycin B. The growth of wild type and pmul mutant strains contain- 
ing factor Xa sites, I”‘EGR, 1275EGR or 1’70EGR/1275EGR was as- 
sessed in YEPD medium containing increasing amounts of hygromycin 
B, as indicated. The amount of growth (Asg,]) in the absence of hy- 
gromycin B was taken as the control level. 
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Fig. 4. Effect of medium pH on the growth of IEGR-containing pmal 
mutants. IEGR-containing pmal mutants were inoculated into YEPD 
medium adjusted to the indicated pH with either 1 M NaOH or 1 M HCI 
and the cells were grown for 24 h at 22°C. The level of growth at pH 5.5 
was taken as the control value. 
levels for I17’EGR and 1275EGR-containing enzymes ap- 
proached wild type, while the double I’70EGR/1275EGR 
mutant was reduced by about 30%, after correcting for the 
level of intact enzyme in the membrane. More prominent 
effects of the mutations were observed upon examining the 
mutant enzymes for vanadate sensitivity, which presum- 
ably reflects the phosphate binding domain of the catalytic 
domain. The I17’EGR mutant enzyme showed I,, values 
for vanadate inhibition which were 25-fold greater than 
wild type, whereas the I 275EGR and I’70EGR/1275EGR 
mutant enzymes showed more than 200-fold decreased 
sensitivity (Fig. 5). The latter result was expected since the 
1275EGR mutation occurs in a region that was previously 
shown to induce vanadate insensitivity [27,44]. 
The characterization data are consistent with the mutant 
enzymes being fully assembled and functional, which en- 
ables them to support cell growth. However, the mutations 
introduced are subtly perturbing, resulting in prominent 
responses to stress conditions (low pH) or inhibitors (hy- 
gromycin, vanadate). 
Table 1 
Kinetic properties of IEGR-containing pmal mutants 
Enzyme V IndX 
( pm01 P, / 
mg per mitt) 
K, ma 
-factor Xa + factor Xa 
Wild type 3.58kO.03 a 1.56 f 0.66 1.14+0.49 
I”‘EGR 2.59_+0.10 1.35kO.33 1.02*0.10 
I”‘EGR 3.28f0.40 1.10+0.21 0.94kO.25 
I’70EGR/I’75EGR 1.51+0.15 1.60f0.51 0.98+0.30 
(2.52+0.25) b 
"n=4. 
b Adjusted for the amount of intact H+-ATPase (M, - 100000) relative 
to wild type. 
Vanadate (PM) 
Fig. 5. Sensitivity of pmal mutant enzymes to vanadate. The hydrolysis 
of H+-ATPases from wild type and IEGR-containing pmnl mutants was 
determined as a function of increasing concentrations of vanadate, as 
indicated. A 100 ~1 reaction medium consisted of IO mM Mes-Tris, pH 
6.5, 5 mM ATP, 5 mM MgSO,, 25 mM NH,Cl and vanadate at O-500 
FM. 
3.2. Factor Xa cleavage of mutant enzymes 
Fig. lB-D shows the effects of treating purified plasma 
membranes containing either I17’EGR, 1’75EGR or 
I17’EGR/ 275EGR factor Xa binding sites with factor Xa 
at 12°C for 18 h. The prolonged incubation time was 
needed because factor Xa does not cleave with high effi- 
ciency. The 12°C temperature enabled the H+-ATPase to 
be incubated for a prolonged time (N 18 h) without suffer- 
ing gross inactivation. Typically, wild type and mutant 
enzymes showed nearly 70% of their original specific 
activities after this treatment. All the mutant enzymes 
showed some degree of factor Xa cleavage with the ap- 
pearance of appropriately sized peptide fragments in 
coomassie stained SDS gels (Fig. 1). Enzyme containing 
I17’EGR was cleaved to a maximum of about 10% with 
the appearance of a 81 kDa fragment (bottom band of 
doublet), while 1275EGR-containing enzyme showed about 
30-35% cleavage and the double mutant 
I’70EGR/1275EGR showed greater than 55% cleavage with 
the appearance of a characteristic 70 kDa fragment. Both 
major fragments, 81 and 70 kDa, cross-reacted with anti- 
body directed at the LOOP1 region (see Section 2). In 
addition, a small amount of an 11 kDa fragment was 
detected with the double mutant, which was consistent 
with the fragment size expected following cleavage at sites 
170 and 275. 
The same overall level of cleavage was observed for 
deoxycholate-extracted mutant enzymes suggesting that a 
sided distribution of membrane vesicles did not account 
for partial proteolysis. It should also be noted that the level 
of cleavage for active enzymes was not due to the presence 
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of denatured enzyme, since cleavage did not correlate with 
the level of residually-inactivated enzyme after incubating 
at 12°C for 18 h. A linear relationship was not observed 
between the level of inactivated enzyme and the degree of 
factor Xa cleavage under standard incubation conditions. 
Factor Xa cleavage saturated after 16- 18 h (at 12”C), 
irrespective of whether enzyme was inactivated or not. 
However, the overall level of cleavage by factor Xa could 
be increased 50% or more for the IZ7’EGR-containing 
mutants by increasing the incubation temperature to 41°C 
or by pre-treating the enzymes with 4 M or 8 M urea. 
Unfortunately, control enzymes prepared under these con- 
ditions were completely inactivated by this treatment. 
These results suggest that the factor Xa site at position 
170 appears highly occluded under normal conditions. In 
contrast. the site at position 275 is more accessible to the 
proteolytic enzyme under native-like conditions. The en- 
hanced cleavage of the double mutant, I’70EGR/I’7sEGR. 
suggests either that cleavage at one site then exposes the 
second site more readily to factor Xa or that the introduc- 
tion of mutations at both positions alters the local structure 
sufficiently such as to expose each site more readily. 
3.3. Eflect of dealage on enzyme ,function 
To assess whether cleavage at factor Xa sites within 
LOOP1 had an affect on the catalytic properties of the 
enzyme, the mutant containing membranes were treated 
with factor Xa and aliquots were removed between 0 and 
20 h for analysis for ATP hydrolysis. Since cleavage of 
pmal mutant enzyme in membranes is incomplete and 
ranges between 10 and 40%, it was expected that only the 
IZ7” EGR and I ‘7”EGR/I 170EGR-containing mutants, 
which show approx. 25 and 45% maximum cleavage, 
would show sufficient cleavage to have an impact on ATP 
hydrolysis. Fig. 6 shows that the specific activity of wild 
type declined in a linear fashion over the 20 h incubation 
period and, as expected, there was no effect of factor Xa 
since no sites were available for cleavage. The I17’EGR-, 
I’7”EGR- and I’75EGR/I’7”EGR-containing mutants also 
showed a progressive inactivation over time but there was 
no effect on activity after factor Xa cleavage. The factor 
Xa-independent inactivation reflected a change in l(,,,, for 
the enzymes. K, (mM) values were essentially unchanged 
before or after factor Xa cleavage. In addition, there was 
no observable change in vanadate sensitivity (I,,) for the 
mutant enzymes following cleavage by factor Xa. These 
data suggest that the LOOP1 region participates in cataly- 
sis even when the peptide backbone is altered in regions 
(IZ7’EGR) believed to be important for phosphate binding 
and release. 
The effect of factor Xa cleavage on ATP-coupled pro- 
ton transport was assessed in H+-ATPase-reconstituted 
vesicles by following the quenching of a&dine orange 
fluorescence. Proton transport could only be assessed in 
the IZ7’EGR-containing mutant because it produced signif- 
25 
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Fig. 6. Effect of factor Xa cleavage on inactivation of the H+-ATPase. 
pmal mutant membranes, as indicated, were incubated with factor Xa 
under standard conditions. Aliquots were removed at 0, 6 and 24 h, and 
assayed for residual H+-ATPase activity. In panels A, B and C. the wild 
type enzyme is represented by the open (cut) and solid (uncut) bars, 
whereas the mutant enzymes are represented by the striped (uncut) and 
gray (cut) bars. 
icant cleavage following treatment with factor Xa to allow 
a reasonable comparison between cut and uncut enzyme. 
The I’70EGR-containing enzyme showed less than 10% 
cleavage which was insufficient to detect a reasonable 
change. On the other hand, the double mutant, 
I’70EGR/I’7’EGR produced greater levels of cleavage, 
but it had relatively low enzyme activities, which pre- 
cluded analysis by the fluorescence quenching assay. Wild 
type and I’75EGR-containing mutant enzymes were recon- 
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Fig. 7. Effect of factor Xa cleavage on proton transport. Highly purified 
H+-ATPases from wild type (A,B) and I”sEGR-containing pmal strains 
(CD) were separately reconstituted in l iposomes (see Section 2). The 
liposomes were assayed for ATP mediated proton transport by the 
acridine orange fluorescence quenching assay (see Section 2). Reconsti- 
tuted vesicles were partitioned into two sets, with one set left untreated 
(A,C), and the other set treated with factor Xa (B,D) under standard 
conditions. The treated vesicles were then assayed for ATP mediated 
proton transport. The reaction was initiated by the addition of a final 
concentration of 5 m M  MgSO,. Vanadate (100 PM) and NH,CI (IO 
mM) were added at a steady state to collapse the pH gradients. The latter 
was only added to the I’75EGR-containing mutant enzymes. 
stituted in liposomes and incubated in the presence or 
absence of factor Xa, under standard cleavage conditions 
(see Section 2). SDS gel electrophoresis was used to 
confirm that the I’75EGR-containing enzyme was cleaved 
suitably by the factor Xa incubation, and that the wild type 
enzyme was unaffected (not shown). It should be noted 
that cleavage was somewhat less (IV 20-25s of total) than 
that observed with plasma membrane vesicles but this was 
expected from an approximate 50-50 orientation of recon- 
stituted enzyme within the liposome bilayer. Only everted 
enzymes, those with their active site regions outside, would 
be transport active and accessible to factor Xa. Taking the 
sidedness factor into account, it is estimated that the 
effective cleavage percentage approached 40-50s. Fig. 7 
shows that ATP-driven proton transport was identical for 
untreated (panel A) and factor Xa-treated wild type en- 
zyme (panel B). A similar result was found for untreated 
(panel C) and treated (panel D) 1275EGR-containing mu- 
tant enzyme. In fact, the initial rate of proton transport was 
slightly greater for the factor Xa treated mutant enzyme, 
which is consistent with it showing somewhat less inacti- 
vation then untreated enzyme (Fig. 6). The addition of 50 
PM vanadate to wild type enzyme reversed the pH gradi- 
ent, as the pump was shut down and protons equilibrated 
across the membrane (Fig. 7A,B). In contrast, vanadate at 
this concentration had no effect on pH gradient formation 
by IZ7’EGR-containing enzyme, as expected from its vana- 
date insensitivity of ATP hydrolysis (Fig. 5). These results 
indicate that cleavage of the protein backbone at amino 
acid position 275 does not uncouple proton transport from 
ATP hydrolysis. 
4. Discussion 
Selective proteolysis has been an effective tool for the 
investigation of conformationally-linked molecular motion 
in P-type transport enzymes [40,41,50]. In general, limited 
proteolysis is used to restrict the site(s) of proteolytic 
cleavage. Since proteolytic enzymes are by themselves 
rather large, there is an underlying assumption that for a 
site to be recognized and cleaved, it must be freely accessi- 
ble to the proteolytic agent. The loss or gain of a recogni- 
tion site upon binding a ligand or upon binding an in- 
hibitor, which freezes the enzyme in a specific conforma- 
tion, has been interpreted to represent conformationally-in- 
duced molecular motion of the local protein structure 
containing the recognition site [41]. This assumes that the 
conformational probe does not interfere sterically with the 
protease-protein complex. We have used the yeast Hi- 
ATPase to selectively introduce unique factor Xa prote- 
olytic sites at defined loci in the cytoplasmic LOOP1 
region linking transmembrane segments 2 and 3. This 
approach permits proteolysis at a defined site in the en- 
zyme without concerns from other potential cleavage sites 
due to the fact that the Hi-ATPase has no endogenous 
factor Xa sites. The ability to selectively introduce unique 
proteolysis sites is important for the HC-ATPase because 
limited proteolysis resulting in selective cleavage at sites 
other than the N- or C-termini has been difficult to achieve; 
it frequently results in multiple sites being rapidly cleaved 
1511. 
The factor Xa sites were introduced by modifying exist- 
ing amino acids within the LOOP1 region by site directed 
mutagenesis of the PMAI gene to create the recognition 
sequence IEGR. Three sites, l”“EGR, 1’““EGR and 
I’75 EGR, were engineered to examine functional and topo- 
logical properties of the LOOPI domain. The LOOP1 
domain displays structural motifs that are strongly pre- 
served in all P-type ion motive ATPases [34]. It is believed 
to have a-helical character at its N- and C-terminal ends, 
extending to and from transmembrane segments 3 and 2, 
respectively, where it forms part of the ‘stalk’ region of 
the cytoplasmic domain [16,52]. The remainder of the 
sequence is predicted to form a P-strand domain that 
interacts with the catalytic ATP binding/phosphorylation 
domain within the large central cytoplasmic domain. The 
I”OEGR site is predicted to lie within the a-helical region 
of the stalk, and within 2-3 turns of the helix extended 
from the bilayer [53]. This site is poorly cut with Factor Xa 
under native conditions, rarely exceeding about 10% cleav- 
age, as determined by the reduction of the intact 100 kDa 
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protein and the appearance of an 81 kDa cleavage product 
(Fig. 1). ATP h d 1 y ro ysis had no affect on the level of 
cleavage at this site suggesting that it has restricted motion 
during catalysis. The I 17’EGR site must be poorly solvent 
exposed or sterically constrained, which limits access of 
the factor Xa enzyme. If the LOOP1 helices comprise 2 of 
the 5 helical elements, which are believed to make up the 
stalk [54], then the organization of this region, perhaps as a 
bundled helical structure, might limit molecular motion 
within the structure. The fact that the multiple amino acid 
substitutions D17’I, L17*G and K17”R required to form the 
factor Xa site had little effect on the overall activity of the 
enzyme suggests that backbone structure and not individ- 
ual side groups are most important in this region. 
The 1254EGR and 1275EGR sites are expected to lie 
toward the C-terminal end of the P-strand region. The 
12j4EGR position approximates the region where trypsin is 
known to cleave the LOOP1 domain in the Ca”-ATPase 
[35,55]. This controversial tryptic sensitive region was 
initially implicated as a potential site of uncoupling [35], 
although more recent studies do not support this conclu- 
sion [35,36]. However, the strongly basic stretch of amino 
acids in the Cal+-ATPase where tryptic cleavage actually 
occurs is absent from the yeast H+-ATPase 161. The intro- 
duction of IEGR at position 254 was sufficiently perturb- 
ing to the enzyme so as to be lethal for cell growth. It is 
not clear whether lethality resulted from the introduction 
of a bulkier Ile at G254, a positively-charged Arg at F257, 
or both. Interestingly, a S*““C(A or V> mutation in this 
region has little effect on the overall catalysis by the 
enzyme (Bandell, Wang and Perlin, unpublished data), 
although a K250T mutation rendered the S. pombe enzyme 
highly vanadate insensitive [56]. Finally, cleavage of the 
H+-ATPase at the nearby IZ7’EGR site had no effect on 
ATP-mediated proton transport (Fig. 71, indicating that this 
region is not likely to be involved directly in coupling via 
a transmittal of conformational energy through its back- 
bone structure and transmembrane segment 3. 
The Iz7”EGR site is predicted to lie near the end of the 
P-strand region. It is considerably more accessible to 
factor Xa, showing 35% or more cleavage of the 100 kDa 
protein with the appearance of a characteristic 70 kDa 
fragment (Fig. 1). When both 1275EGR and I17’EGR are 
present, the level of factor Xa-induced cleavage increases 
to more than 55% with the appearance of the characteristic 
70 kDa fragment, and a minor 11 kDa fragment represent- 
ing most of the LOOP1 domain (amino acids 170-275) 
(Fig. 1). The position of the 1275EGR site is clearly more 
accessible to factor Xa, but as with the 117’EGR site, it 
does not show altered reactivity in the presence of MgATP 
or MgATP + vanadate. Thus, it appears that this region 
does not undergo extensive molecular motion. The appar- 
ent lack of flexibility is somewhat surprising because this 
portion of the LOOP1 domain has been suggested to 
comprise part of the phosphate binding domain, based 
largely on mutations which confer vanadate insensitivity 
[45,56-591 and show altered phosphate interactions [60]. 
Our finding that the introduction of mutations L27”I, V276E, 
N’77G and K278R, which comprise the Iz7”EGR factor Xa 
site, confer prominent vanadate insensitivity to the enzyme 
(Fig. 5) is consistent with these previous findings. It is 
noteworthy that cleavage of the backbone at position 275, 
within the region suggested to be important for phosphate 
binding, had little effect on the overall ATP hydrolysis by 
the enzyme (Fig. 6). We were somewhat surprised that the 
I17’EGR site, which is expected to lie in a completely 
separate structural region, also confers strong vanadate 
insensitivity (Fig. 5). This finding suggests that subtle 
structural perturbations in the LOOP1 domain may alter 
the distribution of conformational intermediates leading to 
vanadate insensitivity, as has been previously proposed 
[27,45]. The effects of these mutations on the steady-state 
distribution of conformational intermediates leading to 
vanadate insensitivity, and reduced catalytic activity for 
the 1275EGR/I’70EGR double mutant are consistent with 
the effects of LOOP1 mutations on the Ca’+-ATPase [48]. 
Perturbations in the LOOP1 domain are believed to 
affect catalytic turnover of the enzyme. Portillo and Ser- 
rano [61] first reported that phosphoenzyme levels in the 
yeast H+-ATPase during steady-state ATP hydrolysis were 
enhanced by an EZ3’N mutation, suggesting a defect in the 
hydrolytic step in this enzyme. A comparable mutation in 
the Ca*+-ATPase did not support this suggestion, rather 
the mutation was found to cause a defect in the E,P-E2P 
transition [48]. Clarke et al. [62] also suggested that an 
alteration of the E,P-E,P transition was responsible for 
catalytic defects observed with mutations in the LOOP1 
P-strand domain. Thus, mutations in the LOOP1 domain 
may alter the progression of catalysis by blocking the 
interconversion of catalytic intermediates. Conformational 
transitions in the LOOP1 domain appear to be an impor- 
tant part of the overall catalytic cycle for the Na+,K+- 
ATPase [41]. It has also been found that the formation of 
E, P exposes the tryptic cleavage site at R198 (M2) in the 
Ca’+-ATPase, whereas the site is largely protected in E,P 
[63]. Finally, proteolytic cleavage of a V8-sensitive site, 
E23 1, on the Ca’+-ATPase prevents conformational 
changes necessary for calcium transport after phosphoryla- 
tion [40], and this finding is similar to the decline in 
calcium transport observed with a site-directed mutation 
N” ‘A [64]. 
It is noteworthy that Goffeau and colleagues [65] suc- 
cessfully expressed the large central catalytic domain as a 
fusion product that could bind nucleotide analogs. How- 
ever, co-expression of the LOOP1 domain did not appear 
to alter the profile of nucleotide analog binding, nor did it 
induce hydrolysis of ATP when present. These experi- 
ments suggest that LOOP1 is not required for nucleotide 
binding, but its role in catalysis remains unclear. 
Finally, the conformational properties of the LOOP1 
domain appear to be most prominent in the putative p- 
strand region. The results in this study suggest that the 
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regions flanking the P-strand region do not undergo signif- 
icant molecular motion, since the accessibility of factor Xa 
sites are unaltered during catalysis. Nonetheless, the intro- 
duction of multiple mutations outside the projected p- 
strand region induces conformational perturbations, which 
appear to alter the distribution of catalytic intermediates 
resulting in vanadate insensitivity. Factor Xa-induced 
cleavage of the protein backbone at the 275 site had 
essentially no effect on ATP hydrolysis or ATP-mediated 
proton transport suggesting that this localized region of the 
LOOP1 structure plays a minor role in coupled catalysis. 
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